NCT01265732View on ClinicalTrials.gov

A Comparison Of The Pharmacokinetics Of PF-04191834 Following Single Dose Administration Of A Dispersion Formulation And A Suspension Formulation In Healthy Volunteers

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2010

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions
Healthy
Interventions
DRUG

PF-04191834

single dose, 100mg, dispersion

DRUG

PF-04191834

single dose, 100mg, suspension

DRUG

PF-04191834

single dose, 300mg, suspension

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY